Travere Therapeutics, Inc. (TVTX)
NASDAQ: TVTX · Real-Time Price · USD
18.25
-0.01 (-0.05%)
Nov 22, 2024, 4:00 PM EST - Market closed
Travere Therapeutics Employees
Travere Therapeutics had 380 employees as of December 31, 2023. The number of employees decreased by 82 or -17.75% compared to the previous year.
Employees
380
Change (1Y)
-82
Growth (1Y)
-17.75%
Revenue / Employee
$535,387
Profits / Employee
-$924,879
Market Cap
1.59B
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
Evotec SE | 5,061 |
InMode | 581 |
BioCryst Pharmaceuticals | 536 |
Immunocore Holdings | 497 |
Dynavax Technologies | 408 |
Kiniksa Pharmaceuticals International, | 297 |
Nurix Therapeutics | 284 |
Neumora Therapeutics | 124 |
TVTX News
- 9 days ago - Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 15 days ago - Travere Therapeutics Announces Pricing of Public Offering of Common Stock - GlobeNewsWire
- 16 days ago - Travere Therapeutics Announces Proposed Public Offering of Common Stock - GlobeNewsWire
- 18 days ago - Travere Therapeutics to Present at Upcoming Investor Conferences - GlobeNewsWire
- 23 days ago - Travere Therapeutics, Inc. (TVTX) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 4 weeks ago - Travere Therapeutics Presents Data Reinforcing Clinical Benefit of FILSPARI® (Sparsentan) in IgAN and Late-Breaking Presentation in FSGS at ASN Kidney Week 2024 - GlobeNewsWire
- 4 weeks ago - Travere Therapeutics to Report Third Quarter 2024 Financial Results - GlobeNewsWire
- 5 weeks ago - Travere Therapeutics and CSL Vifor Announce Swissmedic Approval of FILSPARI® (sparsentan) for the Treatment of IgA Nephropathy - GlobeNewsWire